Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Natesto, Tuzistram, ZolpiMist and MiOXSYS.
P/E
Net profit
P/B
Book value
Debts
Net debt
Yield
Growth potential
Aytu BioPharma news
15.02.2022
Aytu BioPharma's GAAP loss for 6 months of fiscal year 2022 was $39.399 million, up 2.8 times from $13.831 million in the previous year. Revenue increased 57.1% to $45.022 million from $28.667 million a year earlier.
Source: 
irdirect.net
irdirect.net
08.12.2021
FDA has granted orphan drug status to Aytu BioPharma's drug AR101. It is being developed for the treatment of Ehlers-Danlos syndrome. The status gives the company market exclusivity in the U.S. for up to seven years after FDA approval of the drug.
Source: irdirect.net
irdirect.net
16.11.2021
Aytu BioPharma's GAAP loss for 3M 2022 fiscal year was $27.851 million, up 6.5 times from $4.306 million in the previous year. Revenue increased 62% to $21.897 million from $13.52 million a year earlier.
Source: irdirect.net
irdirect.net
28.09.2021
Aytu BioPharma's GAAP loss for fiscal year 2021 was $58.289 million, up 4.3 times from $13.621 million in the previous year. Revenue increased 2.4 times to $65.632 million from $27.632 million a year earlier.
Source: irdirect.net
irdirect.net
General information
| Company name | Aytu BioPharma |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112 (720) 437-6580 |
| Mailing address | 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112 |
| Website | www.aytubio.com |
| Information disclosure | www.sec.gov |
English (US) 